Battle Lines Clear On Conflict Of Interest Policy In PDUFA Reauthorization
This article was originally published in The Tan Sheet
Executive Summary
Commissioner Hamburg says the agency likely does not need legislation to improve its conflict of interest policy, but House members still say the system needs reform. Industry and patient advocate groups push for change, while consumer groups press FDA to stand firm.
You may also be interested in...
PDUFA V: Can FDA Fight Off Mission Creep This Cycle?
As hearings get under way, Commissioner Hamburg says considering the jobs affected by the approval or denial of an application would be difficult and inappropriate.
Conflict Of Interest Reform: With FDA Undecided, Consumer Groups Give Their Pitch
FDA likes some rules in FDAAA and wants to continue discussion with Capitol Hill as changes are expected to be part of PDUFA legislation.
Drug Shortage Bills Likely Drivers Of PDUFA Add-ons
Rep. Burgess says there appears to be enough bipartisan support for dealing with the shortage problem that it almost certainly will be added to the reauthorizing legislation.